Belluscura looks to wound care market
By HME News Staff
Updated 9:11 AM CST, Wed December 4, 2024
LONDON - Belluscura has entered into a joint venture with Separation Design Group and an undisclosed major medical device company to develop oxygen-based wound care solutions. The collaboration aims to address the growing wound care market through innovative treatments, including continuously diffused oxygen (CDO) therapy, which has shown potential in healing chronic wounds such as diabetic foot ulcers. The joint venture, in which Belluscura will act as the original equipment manufacturer (OEM), is backed by the major medical device company's commitment to fund product development, clinical trials and distribution following regulatory approval. Bob Rauker, CEO of Belluscura, said the venture has the potential to leverage the company’s technology across broader health care applications, addressing the substantial and growing need in the wound care market. The first clinical study is expected to begin outside the United States in early Q2 2025.
Comments